BR112019005040A2 - aplicação de pridopidina para tratamento de síndrome de rett - Google Patents

aplicação de pridopidina para tratamento de síndrome de rett

Info

Publication number
BR112019005040A2
BR112019005040A2 BR112019005040A BR112019005040A BR112019005040A2 BR 112019005040 A2 BR112019005040 A2 BR 112019005040A2 BR 112019005040 A BR112019005040 A BR 112019005040A BR 112019005040 A BR112019005040 A BR 112019005040A BR 112019005040 A2 BR112019005040 A2 BR 112019005040A2
Authority
BR
Brazil
Prior art keywords
pridopidine
application
rett syndrome
syndrome treatment
individual
Prior art date
Application number
BR112019005040A
Other languages
English (en)
Portuguese (pt)
Inventor
Den Michael
Geva Michal
Laufer Ralph
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of BR112019005040A2 publication Critical patent/BR112019005040A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
BR112019005040A 2016-09-16 2017-09-15 aplicação de pridopidina para tratamento de síndrome de rett BR112019005040A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
BR112019005040A2 true BR112019005040A2 (pt) 2019-07-16

Family

ID=61619744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005040A BR112019005040A2 (pt) 2016-09-16 2017-09-15 aplicação de pridopidina para tratamento de síndrome de rett

Country Status (13)

Country Link
EP (2) EP3512506B1 (https=)
JP (1) JP6977029B2 (https=)
CN (1) CN109982686A (https=)
AU (1) AU2017326013B2 (https=)
BR (1) BR112019005040A2 (https=)
CA (1) CA3036984C (https=)
DK (2) DK3512506T3 (https=)
ES (2) ES2909557T3 (https=)
HU (1) HUE058314T2 (https=)
IL (1) IL265342B2 (https=)
MX (1) MX388845B (https=)
PL (2) PL4005570T3 (https=)
WO (1) WO2018053280A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20161220A1 (es) * 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
PL3512506T3 (pl) 2022-05-30
IL265342A (en) 2019-05-30
JP2019532926A (ja) 2019-11-14
EP4005570B1 (en) 2024-05-15
MX388845B (es) 2025-03-20
HUE058314T2 (hu) 2022-07-28
JP6977029B2 (ja) 2021-12-08
AU2017326013A1 (en) 2019-04-11
EP3512506A4 (en) 2020-05-27
CN109982686A (zh) 2019-07-05
ES2909557T3 (es) 2022-05-09
DK4005570T3 (da) 2024-08-19
PL4005570T3 (pl) 2024-09-23
AU2017326013B2 (en) 2020-12-24
EP3512506B1 (en) 2022-01-26
CA3036984C (en) 2023-07-18
WO2018053280A1 (en) 2018-03-22
DK3512506T3 (da) 2022-04-19
ES2986807T3 (es) 2024-11-12
IL265342B2 (en) 2023-06-01
EP4005570A1 (en) 2022-06-01
EP3512506A1 (en) 2019-07-24
CA3036984A1 (en) 2018-03-22
MX2019003069A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
EA201890204A1 (ru) Антибактериальные соединения
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PE20180260A1 (es) Metodos y kits para tratar la depresion
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201500940A1 (ru) Усовершенствованная композиция для заживления ран и лечение
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
BR112016012248A2 (pt) método de tratamento de nefropatia
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
BR112019008241A2 (pt) tratamento do prurigo nodular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: PRILENIA NEUROTHERAPEUTICS LTD. (IL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.